Dr. Martin Madaus Joins Quanterix as CEO

CAMBRIDGE, Mass., Sept. 19, 2011 /PRNewswire/ -- Quanterix Corporation, using its revolutionary Single Molecule Array (SiMoA™) technology to enable unprecedented high value research and diagnostic products based on its ultrasensitive protein detection platform, announced today that Martin D. Madaus, Ph.D. has joined the company as Chief Executive Officer.  Dr. Madaus, who also retains his position as Chairman, brings more than 20 years of experience in the diagnostics and life science industries, most recently serving as President, Chairman and CEO of Millipore Corporation, acquired by Merck KGaA last year for $7 billion.  Before joining Millipore, Dr. Madaus was President, CEO and head of North American Operations for Roche Diagnostics Corporation.  

"Quanterix recently announced partnerships to develop and manufacture a fully-automated instrument and 'smart consumables' for use in both the life sciences research and diagnostics markets.  Martin brings significant financial and commercial expertise that will be invaluable as the company executes its plan to launch the SiMoA platform, and we are thrilled to have Martin on board," said David Walt, Ph.D., Scientific Founder of Quanterix.

"I am very excited to lead Quanterix to realize its tremendous commercial potential.  Having been a member of the Board since 2010, I have seen first-hand the exceptional technical progress Quanterix has made.  I am convinced that the Quanterix platform will help research scientists and clinicians to overcome the limitations of current detection platforms and enable new medical breakthroughs.  The simplicity and unparalleled sensitivity of the single molecule detection principle will enable us to build a range of products for research and IVD use," said Dr. Martin Madaus.  "I look forward to working more closely with the highly talented Quanterix team in building a new molecular diagnostics company."

James Nahirny, Managing Director of Bain Capital Ventures and Quanterix Board member added, "The Board of Directors is delighted that Martin has decided to step into this new role.  He has an extraordinary track record of driving innovation and delivering shareholder returns, and we are confident that under his leadership Quanterix is well positioned to bring the promise of SiMoA and the 1,000-fold improvement in sensitivity enabled by this technology to commercial success."  

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.

SOURCE Quanterix Corporation